Skip Navigation


Cardiovascular Research Advance Access originally published online on January 10, 2008
Cardiovascular Research 2008 77(4):614-615; doi:10.1093/cvr/cvn003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
77/4/614    most recent
cvn003v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Levy, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench

Yishai Levy

Department Medicine D Lipid Disorders Clinic Rambam Health Care Campus Bat Galim, P.O. Box 31096 Haifa 35254 Israel and The Ruth and Bruce Rappaport Faculty of Medicine Technion – Institute of Technology, Efron St. P.O. Box 9649, Bat Galim Haifa 31096 Israel

Corresponding author. Tel: +972 4 854 2263; fax: +972 4 854 3286. E-mail address: ys_levy@rambam.health.gov.il

The first 10% of the full text of this article appears below.

In December 2006, the ILLUMINATE study was unexpectedly terminated because of excess mortality in the treatment group. In this study, which enrolled more than 15 000 patients, the leading cholesteryl ester transport protein (CETP) inhibitor Torcetrapib, plus Atorvastatin, was compared with Atorvastatin plus placebo in a high cardiovascular risk population. An impressive response with a 72.1% increase in high-density lipoprotein (HDL)–cholesterol accompanied by a 24.9% decrease in low-density lipoprotein (LDL)–cholesterol was demonstrated. However, a 25% increased rate of cardiovascular events and a 40% increase in cardiovascular death occurred, and mortality due to noncardiovascular events was doubled.1 Other trials failed to show any benefit of Torcetrapib in the postponement of atherosclerosis . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?